ReoPro abciximab: Marketed

Johnson & Johnson (JNJ, New Brunswick, N.J.) subsidiary Centocor reported that at a 3-year follow-up analysis, the mortality rate

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE